Loading...
XNAS
ALNY
Market cap39bUSD
Jun 13, Last price  
307.99USD
1D
2.04%
1Q
26.02%
Jan 2017
713.76%
IPO
4,252.43%
Name

Alnylam Pharmaceuticals Inc

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
17.86
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.31%
Rev. gr., 5y
59.21%
Revenues
2.25b
+22.97%
5,716,00026,930,00050,897,00096,163,000100,533,000100,041,00082,757,00066,725,00047,167,00050,561,00041,097,00047,159,00089,912,00074,908,000219,750,000492,853,000844,287,0001,037,418,0001,828,292,0002,248,243,000
Net income
-278m
L-36.82%
-42,914,000-34,608,000-85,466,000-26,249,000-47,590,000-43,515,000-57,649,000-106,014,000-89,225,000-360,395,000-290,073,000-410,108,000-490,874,000-761,497,000-886,116,000-858,281,000-852,824,000-1,131,156,000-440,242,000-278,157,000
CFO
-8m
L
-16,485,000-24,630,000196,519,00065,491,000-72,145,000-84,341,000-87,068,000-115,609,000-68,657,000-165,641,000-189,140,000-307,701,000-382,786,000-562,616,000-278,427,000-614,961,000-641,693,000-541,274,000104,156,000-8,312,000
Earnings
Jul 30, 2025

Profile

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
URL
https://www.alnylam.com/
IPO date
May 28, 2004
Employees
2,002
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,248,243
22.97%
1,828,292
76.23%
1,037,418
22.88%
Cost of revenue
2,425,128
2,110,467
1,822,490
Unusual Expense (Income)
NOPBT
(176,885)
(282,175)
(785,072)
NOPBT Margin
Operating Taxes
99,218
6,725
4,163
Tax Rate
NOPAT
(276,103)
(288,900)
(789,235)
Net income
(278,157)
-36.82%
(440,242)
-61.08%
(1,131,156)
32.64%
Dividends
Dividend yield
Proceeds from repurchase of equity
147,464
259,360
BB yield
-0.62%
-0.90%
Debt
Debt current
41,886
96,501
41,967
Long-term debt
271,427
2,870,736
1,581,587
Deferred revenue
188,175
193,791
Other long-term liabilities
2,986,623
308,438
1,464,595
Net debt
(2,381,191)
527,855
1,990,513
Cash flow
Cash from operating activities
(8,312)
104,156
(541,274)
CAPEX
(34,277)
(62,211)
(72,059)
Cash from investing activities
(116,840)
(336,350)
169,354
Cash from financing activities
294,159
172,131
425,753
FCF
(244,246)
(276,059)
(794,232)
Balance
Cash
2,694,504
2,439,382
2,192,406
Long term investments
(2,559,365)
Excess cash
2,582,092
2,347,967
Stockholders' equity
1,293
(7,031,707)
(6,612,763)
Invested Capital
3,094,304
9,990,302
9,433,174
ROIC
ROCE
EV
Common stock shares outstanding
128,590
124,906
121,689
Price
235.31
22.94%
191.41
-19.46%
237.65
40.14%
Market cap
30,258,513
26.56%
23,908,257
-17.33%
28,919,391
43.97%
EV
27,877,322
24,436,112
30,909,904
EBITDA
(120,215)
(185,144)
(699,522)
EV/EBITDA
Interest
141,858
121,221
155,968
Interest/NOPBT